Document Detail

Alterations in anterior chamber depth in primary open-angle glaucoma patients during latanoprost therapy.
MedLine Citation:
PMID:  19860780     Owner:  NLM     Status:  MEDLINE    
PURPOSE: The aim of this study was to evaluate changes in the anterior chamber depth (ACD) in primary open-angle glaucoma (POAG) patients during latanoprost therapy.
METHODS: We carried out a prospective study in which we enrolled 66 newly diagnosed POAG patients treated with latanoprost 0.005% (group 1) and 50 ocular hypertensive and ⁄ or glaucoma suspect cases who were given no therapy (group 2 [control]). Measurements of the ACD were performed by A-scan ultrasonography before and after cycloplegia at baseline and at 3 months of latanoprost therapy. Differences in ACD and their correlations with the ocular hypotensive effect of the agent as well as the clinical significance of changes in ACD were analysed using Student’s t-test and Pearson’s correlation coefficient. Statistical significance was set at p < 0.05.
RESULTS: Mean baseline ACD was 3.13 ± 0.35 mm (range 2.45–3.84 mm) in group 1 and 3.14 ± 0.36 mm (range 2.54–3.80 mm) in group 2 (p = 0.89). At 1 hour after instillation of cyclopentolate 1%, mean ACD in groups 1 and 2 was 3.18 ± 0.38 mm (range 2.45–3.92 mm) and 3.19 ± 0.37 mm (range 2.56–3.91 mm), respectively (p = 0.91). After 3 months of treatment, mean ACD in group 1 both without (3.05 ± 0.36 mm, range 2.14–3.76 mm) and with (3.09 ± 0.4 mm, range 2.20–3.96 mm) cycloplegia was significantly reduced compared with baseline values (p < 0.001 for both). However, there was no significant difference between mean ACD at baseline and that at month 3 in group 2. No correlation was demonstrated between the changes in ACD and the ocular hypotensive effect of latanoprost (p = 0.96, r = – 0.006). There were no changes in refractive status or visual acuity.
CONCLUSIONS: The overall results seem to suggest that latanoprost decreases mean ACD in patients with POAG. The clinical significance of this effect is uncertain.
Ali Bulent Cankaya; Pinar Teberik; Golge Acaroglu
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Acta ophthalmologica     Volume:  89     ISSN:  1755-3768     ISO Abbreviation:  Acta Ophthalmol     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-04-19     Completed Date:  2011-06-16     Revised Date:  2012-03-06    
Medline Journal Info:
Nlm Unique ID:  101468102     Medline TA:  Acta Ophthalmol     Country:  England    
Other Details:
Languages:  eng     Pagination:  274-7     Citation Subset:  IM    
Copyright Information:
© 2009 The Authors. Journal compilation © 2009 Acta Ophthalmol.
Second Eye Clinic, Ulucanlar Eye Research Hospital, Ankara, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anterior Chamber / drug effects*,  ultrasonography
Antihypertensive Agents / administration & dosage*
Cross-Sectional Studies
Glaucoma, Open-Angle / drug therapy*
Intraocular Pressure / drug effects
Middle Aged
Ocular Hypertension / drug therapy
Ophthalmic Solutions / administration & dosage
Prospective Studies
Prostaglandins F, Synthetic / administration & dosage*
Refraction, Ocular / physiology
Visual Acuity / physiology
Reg. No./Substance:
0/Antihypertensive Agents; 0/Ophthalmic Solutions; 0/Prostaglandins F, Synthetic; 130209-82-4/latanoprost
Comment In:
Acta Ophthalmol. 2012 Feb;90(1):e76-7; author reply e77   [PMID:  22289195 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Ocular blood flow assessment using continuous laser Doppler flowmetry.
Next Document:  Longterm follow-up of pars plana vitrectomy for vitreous floaters: complications, outcomes and patie...